Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #8328
Reference
MSAN(2024)63
Name
NovoRapid® (insulin aspart) FlexTouch® 100units/ml solution for injection 3ml pre-filled pens (superseded)
Categories
Scottish Government
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
Scotland
Health Boards
Pharmaceutical Services
Supplies
Drug Shortages
Description
NovoRapid® (insulin aspart) FlexTouch® 100units/ml solution for injection 3ml pre-filled pens are being discontinued; stock is anticipated to be exhausted by March 2025.
NovoRapid® (insulin aspart) FlexPen® 100 units/ml solution for injection 3ml pre-filled pens remain available and can support a full increase in demand.
NovoRapid® (insulin aspart) Penfill® 100 units/ml solution for injection 3ml cartridges remain available and can support a full increase in demand.
Insulin aspart biosimilar, Trurapi® (100units/ml solution for injection in 3ml pre-filled SoloStar® pens and 3ml cartridges) remain available and can support a full increase in demand.
This is the first of three MSANs covering discontinuations with Novo Nordisk insulin products (NovoRapid® FlexTouch®, Insulatard® Penfill® and all Levemir® presentations). The remaining MSANs will be issued shortly. It should be noted that where alternative insulin products have been recommended consideration has been made both to these product discontinuations and the wider supply availability of insulin.
This letter has been superseded by MSAN(2025)01.
This letter has been superseded by MSAN(2025)01.
Contact Name
Contact Email
Contact Address
Created
2024-11-22 14:18:00
Click to go back to homepage